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Transgenic mice that developed adrenocorticotropic
hormone (ACTH)-producing pituitary tumors were
generated with the polyoma early region promotor
linked to a cDNA encoding polyoma large T antigen
(PyLT). Light microscopic examination of the pitu-
itaries showed normal morphology at 4 months of
age, either unremarkable morphology or microade-
nomaformation at9 months ofage, and up to 5 mm
large adenomas in clinically ill transgenic mice at
13-16 months of age. At age 9 months, transgenic
mice weighed significantly more than corresponding
control mice, but they began wasting at approxi-
mately I year of age. The adrenal glands of these
older PyLT-1 mice showed a weight increase and ex-
hibited a medullary hyperplasia Subcutaneous
transplants of transgenic pituitary tumors to non-
transgenic, immunocompetent mice resulted in tu-
mors with a morphology andACTH immunoreactiv-
ity similar to the primary tumor. The effects of hy-
percorticotropism were more enhanced and occurred
with a shorter latency in the mice carrying transgene
pituitary transplants than in the PyLT-1 transgenic
mice themselves. Moreover, these transplanted mice
showed a weight increase with an axial deposition
pattern and hypertrophy of the adrenal cortex that
resembled the findings in human Cushing's disease.
Plasma ACTH levels were significantly increased in
clinically ill transgenic mice and even higher levels
were found in the transplant mice. Thus both mu-
rine models should be useful for studying Cushing's
disease. (AmJPathol 1992, 140:1071-1080)
The hypothalamus, pituitary gland and adrenal cortex
constitute an endocrine axis. A hypothalamic peptide,
corticotropin-releasing hormone (CRH),1 stimulates the
pituitary to secrete adrenocorticotropic hormone (ACTH);
ACTH stimulates the adrenal cortex to produce and se-
crete glucocorticosteroids. Chronic ACTH overstimula-
tion of the adrenal cortex induces the steroidogenic path-
way by enhancing gene transcription of the involved en-
zymes.2 Glucocorticoids are normally elevated in
response to stress and fasting. In fasting, corticosteroids
maintain blood glucose by stimulating gluconeogenesis.
Feeding in the presence of high concentrations of gluco-
corticoids may cause hyperglycemia, leading to hyper-
insulinism that in turn results in a central deposition of fat.3
Cushing's syndrome is the clinical result of chronic
overexposure to endogenous cortisol (e.g., an adrenal
cortical adenoma) or prolonged administration of syn-
thetic glucocorticoids in humans. The latter is seen in
large groups of patients treated for chronic autoimmune
diseases, patients with serious allergies such as asthma,
and certain groups of cancer patients. The side effects of
glucocorticoid therapy often limit the therapeutic useful-
ness of the drugs. Excessive pituitary secretion of ACTH
is called Cushing's disease and most often results from a
pituitary tumor, usually designated as a microadenoma.
The more common symptoms of the disease are truncal
obesity, hypertension, hyperglycemia, muscular weak-
ness, and dystrophic skin changes. Measurement of
ACTH levels in plasma from the inferior petrosal sinuses
can distinguish ACTH-secreting pituitary tumors from
other causes of hyperadrenocorticotropism.4 Microade-
nomas can be removed selectively through a transsphe-
noidal resection, leaving normal gland in situ. For the few
patients with a vessel plexus surrounding the pituitary
gland5 and for patients with macroadenomas,6 trans-
sphenoidal surgery may be impossible or insufficient.
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Adjunctive therapies with radiation and drugs that de-
crease ACTH secretion or inhibit corticosteroid synthesis
are available, but they have major shortcomings in terms
of efficiency and side effects.7
Therefore, animal models for Cushing's syndrome
and Cushing's disease are relevant for investigating in
detail the systemic effects of ACTH and glucocorticoids
and new treatment modalities. We have generated trans-
genic mice with a polyoma large T-antigen cDNA trans-
gene that heritably form pituitary tumors with detectable
symptoms at about 1 year of age. The pituitary tumor and
the testes express the PyLT transgene at the mRNA level
(VLB unpublished results). We have shown both at the
light- and electron microscopic level that these tumors
produce ACTH (R. Holm, unpublished results). We report
that the PyLT-1 transgenic mice and immunocompetent
mice carrying transplanted transgenic pituitary tumors
show changes in total body weight, adrenal weight, and
histology of several organs. In addition, the transplant
mice have an axial fat deposition pattern and adrenal
cortex hypertrophy. The circulating levels of ACTH are
markedly increased in both transgenic and transplant
mice. These mice may therefore be useful models for




Transgenic mice were generated as described8 by mi-
croinjection of the polyoma (Py) early region promotor
linked to the cDNA encoding Py large T (PyLT) into the
male pronuclei of fertilized eggs. The cDNA has a dele-
tion in the late region and at the origin of replication that
prevents autonomous replication. Transgenic pups in a
litter were identified by the presence of PyLT in their ge-
nomic DNA. The DNA was isolated from tail biopsies
taken at 2 weeks of age, digested with Hindlll, transferred
to nitrocellulose and hybridized with a 32P-labelled probe
against the Py sequences.8 Nontransgenic mice were
used as control animals in the study. The mice were kept
in a room with humidified and filtered air together with
other transgenic lineages. The facility is approved by the
American Association for Accreditation for Laboratory
Animal Care (AAALAC) and is under the care of Dr. J.
Pick. The mice had food and water ad libitum and were
inspected on a daily basis. Mice were anesthetized with
0.65 ml 2.5% avertin per 30 g animal weight (100% aver-
tin is a weight/volume formulation composed of 5g 2,2,2
tribromoethanol (Aldrich Chemical Company Inc., WI) in
10 ml 2-methyl-2-butanol (Fluka Chemical Corp., NY)).
The time course of weights and morphology were ana-
lyzed by killing transgenic mice together with age- and
sex-matched controls at 4 and 9 months of age in addi-
tion to sick mice. Each group contained 4-5 experimen-
tal mice and 3-6 control mice.
Transplant Mice
Pituitary tumors were carefully excised from the trans-
genic animal (PyLT-1), minced with fine scissors and
rinsed in sterile saline. Tumor pieces were further minced
with sterile scalpel blades and forced through a 1 9G hy-
podermic needle before subcutaneous injection of 0.1 ml
tumor slurry into 6-10 week B6D2F1 nontransgenic fe-
male mice (first passage). Tumors were passaged four
times using this technique, using 3-4 week old B6D2F1
mice in passages 3 and 4. Between 4 and 15 test ani-
mals were transplanted in each experiment and accom-
panied by 3-5 controls. All transplant mice were females
except for the third passage in which both genders were
used. The transplant mice were weighed every 2-4
weeks, and the implant site was both inspected and pal-
pated. Five months after transplantation all the third pas-
sage animals were anesthetized, and tumor diameter
was measured. A group of six randomly chosen female
transplant mice were autopsied at this point. The remain-
ing nine females and eight males were followed for an
additional 3 months.
Pathology
After lethal anesthesia, blood samples were obtained
and the mice were subjected to complete autopsy. The
organs were quickly removed, the weights were re-
corded after excess fat was trimmed, the specimens
were fixed in 10% buffered formalin (Tissue-Fixx, Lerner
Laboratories, PA), and they were processed for paraffin
embedding or fixed and processed for ultrastructural
analyses (R. Holm, unpublished results). The paraffin
sections were stained in batches with H&E. Tumor spec-
imens from five representative cases (two PyLT-1 mice
and three mice receiving subcutaneous transplants)
were processed for immunohistochemical demonstration
of the anterior pituitary hormones using standardized
techniques as previously described.910 The antibodies
were used in the commercially available prediluted
forms: ACTH and PRL (both from Lipshaw, Detroit, Ml),
TSH, FSH, LH, and GH (all from Biomedica, Foster City,
CA).
ACTH Measurement
Blood was obtained by heart puncture, transferred to
chilled microfuge tubes, centrifuged and heparin plasma
was stored at - 70 C until assayed. ACTH was measured
using a double-antibody radioimmunoassay (RIA) as de-
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scribed by Nicholson et al.11 The immunoreagents (hu-
man ACTH antiserum #AFP 6328031, human ACTH
#AFP 2938C for iodination and rat reference preparation
#rACTH-RP-1) were supplied by the National Hormone
and Pituitary Program (NHPP) at the University of Mary-
land School of Medicine and the National Institute of Di-
abetes and Digestive and Kidney Diseases (NIDDK).
Statistical Analysis
The relationship between the mean weights of the exper-
imental and the control animal groups were evaluated
nonparametrically using the Mann-Whitney two sample
test in the NCSS 5.1 Graphics programme (Dr. J. L.
Hintze, Kaysville, Utah 84037). A value of P < 0.05 was
considered significant.
Results
Of the two transgenic mouse lineages generated with
PyLT cDNA microinjection,6 12 mice of one lineage
(PyLT-1) developed pituitary tumors with a complete pen-
etrance and a long latency (lifespan approximately 14
months). Mice of the second lineage (PyLT-2) developed
a similar pituitary microadenoma but with a much lower
penetrance of the phenotype (VLB, unpublished results).
The PyLT-1 line is investigated here.
Weight Changes of Transgenic PyLT-1
Mice
To study the time course of the histomorphology in the
pituitary gland and in organs affected by ACTH overpro-
duction, symptom-free transgenic mice at 4 and 9
months of age were studied in addition to sick transgenic
mice and compared with nontransgenic matched con-
trols. The early signs of the PyLT-1 phenotype were an
enlarged penis and enlarged scrotal pads in males,
whereas female mice did not show specific early signs
(VLB, unpublished results). When the mice became clin-
ically ill, they huddled together, they developed both a
spinal hump in the thoracic region and an unsteady gait,
they showed fur changes (loss of hair and shine), and
they had difficulty in easily reaching food and water. Sick
mice deteriorated rapidly and were killed quickly after
serious symptoms developed. The mean age (and stan-
dard deviation) at the time of autopsy for these animals
was 15.5 (0.9) months for males and 13.1 (2.4) months for
females. The age difference between the genders ap-
proached statistical significance (P = 0.0679).
Table 1 gives the weights of transgenic and control
mice according to age and sex. Both male and female
PyLT-1 mice showed a peak in total body weight at 9
months with subsequent weight loss. The difference be-
tween body weight of the experimental and the control
group was statistically significant for females (weight loss)
at 12 months (P = 0.0143) and for males (weight in-
crease) at 9 months (P = 0.0339). Furthermore, at 9
months the increased body weight for female PyLT-1
mice approached statistical significance (P = 0.083).
The mean weight of the adrenal glands increased with
age in PyLT-1 female mice contrary to the stable trend in
the control mice, and the difference was statistically sig-
nificant at both 9 (P = 0.0209) and 12 months of age (P
= 0.0209). For males, only the sick PyLT-1 mice differed
from their control group (P = 0.0106) in adrenal weight.
These findings are illustrated in Figure 1 where the total
and adrenal weights are shown as the percentage of the
corresponding control values. None of the groups dif-
Table 1. Weight Data: Differences Between Transgenic and ControlMice*
Weight (SD)
Sex Mice 4 months 9 months 12 months
Body weight (g) F PyLT-1 25.91 (3.09) 36.58 (6.96) 19.65 (2.29)t
Control 25.45 (0.47) 29.42 (3.53) 28.51 (2.53)
M PyLT-1 32.41 (1.44) 45.78 (2.17)t 38.04 (2.63)
Control 34.99 (1.27) 36.59 (2.14) 43.38 (6.45)
Adrenals (mg) F PyLT-1 6.72 (0.84) 7.80 (0.79)t 10.43 (1.36)t
Control 6.30 (0.26) 5.98 (0.63) 5.85 (0.97)
M PyLT-1 5.14 (1.10) 4.75 (0.35) 7.80 (1.85)t
Control 5.00 (0.87) 4.60 (0.95) 4.80 (1.01)
Ovaries (mg) F PyLT-1 10.92 (1.89) 14.93 (2.91) 8.50 (2.94)
Control 12.77 (0.68) 13.08 (2.89) 12.00 (3.79)
Testes (g) M PyLT-1 0.22 (0.02) 0.21 (0.01) 0.18 (0.04)
Control 0.23 (0.03) 0.22 (0.01) 0.24 (0.05)
Liver (g) F PyLT-1 1.16 (0.15) 1.49 (0.22) 1.01 (0.28)
Control 1.09 (0.07) 1.28 (0.14) 1.21 (0.12)
M PyLT-1 1.58 (0.08)t 1.94 (0.32) 1.94 (0.24)
Control 1.93 (0.15) 1.59 (0.05) 1.92 (0.28)
The data were analyzed between the transgenic and the control mice for each sex.
t P < 0.05.
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Body weights as percent of
control values
















-_ Figure 1. The body weights (left) and adrenal
.12 weights (right) of male (M) and female (F)
transgenic mice expressed as percentage of
corresponding control values.
fered statistically from control mice in weights of ovaries
and testes (Table 1). The liver weights revealed a signif-
icantly higher weight for control males at the age of 4
months (P = 0.0253) (Table 1). Taken together, these
data show that a peak in total body weight precedes the
onset of serious symptoms and that the adrenal gland
weights increase as the total body weights decrease in
the oldest age group of PyLT-1 mice.
Pathology of Transgenic Mice
Pituitary and adrenal glands were examined by light mi-
croscopy both in the mice with macroscopic pituitary tu-
mors and in the 4- and 9-month old asymptomatic mice.
Due to the known importance of the pituitary-adrenal axis
in the regulation and synthesis of sex hormones, histo-
pathologic evaluation of the ovaries and testis was also
performed. Furthermore, since the liver is central to glu-
coneogenesis and the kidney is the target organ for min-
eralcorticosteroids, these organs were also examined.
Age 4 Months
The pituitary glands of the transgenic mice (Figure 2A)
had an architectural arrangement and cell distribution
similar to that of the control mice. Specifically, no tumors
or hyperplastic foci were observed. The adrenal glands
did not show morphologic changes specific for the ex-
perimental group (Figure 2E). Both groups of mice in-
cluded adrenal glands with subcapsular infiltration of
small, mononuclear cells and minor degenerative
changes in the reticular layer of the cortex. Sections from
testis, ovary, liver, and kidney showed normal morphol-
ogy, except for the finding of a unilateral cystic kidney in
one transgenic animal (data not shown).
Age 9 Months
Of the four pituitary samples processed for light mi-
croscopic examination in this group, two were without
morphologic changes, one showed a small nodule of hy-
perplastic cells, and one sample was classified as a mi-
croadenoma (Figure 2B). Both the nodule and the mi-
croadenoma were not obviously encapsulated. The ad-
enoma cells varied in size and shape and were mainly
organized in groups. Some mitotic figures and small ne-
crotic areas were seen within this lesion.
Sections from male adrenal glands showed some in-
crease in vacuolization of the cortical cell cytoplasm rel-
ative to the control adrenals. This vacuolization was more
apparent in female adrenals, and in one out of three or-
gans a minimal apparent medullary hyperplasia was also
found (Figure 2F). The medullary changes consisted of
nodules of large cells with darker cytoplasm than the or-
dinary medullary cells. Some mitotic figures were seen in
the nodules. Sections from testis, ovary, liver, and kidney
showed unremarkable morphology.
Clinically Mice (Mean Age: 13-16 Months)
All mice had pituitary tumors that were round, soft,
and up to 5 mm in diameter. Grossly, the surface was
dark red to brown, and sagittal sections through the tu-
mor and cerebral hemispheres showed compression of
neighboring structures. Microscopically, the tumor re-
sembled an adenoma as characterized by groups and
cords of tumor cells nested around centrally located
blood vessels (Figure 2C, and Figure 4 for example of
blood vessel). Mitotic figures were sparse. The tumor bor-
der showed compressed tissue but no genuine capsule.
Many pituitary tumor cells showed a weak positive immu-
noreactivity for ACTH in the cytoplasm. In a minority of the
cells, the reaction was intense (Figure 2D). No immuno-
reactivity was found in the cells of interest with antibodies
against GH, PRL, LH, FSH, or TSH.
In five of the seven adrenal samples in this group,
both the cortex and the medulla could be satisfactory
evaluated. There was some nodular hyperplasia of the
medulla in two samples and marked hyperplasia in an-
other two samples. One of these samples also showed
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Figure 2. Light microscopy of pituitary (A-D) and adrenal (E-H) glands. Representative sections of: A: Unremarkable pituitary in a
4-month-old PyLT-1, B: Microadenoma (whole photographic field) in a 9-month-old PyLT-1, C: Macroadenoma in an aged PyLT-1 trans-
genic mouse, D: ACTH-positive immunoreactivity in a PyLT-1 pituitary tumor. E: Histologically unremarkable adrenal in a 4-month-old
PyLT-1 (note medulla in bottom center). F: Adrenal with nodular medullary hyperplasia in a 9-month-oldfemale PyLT-1. G: Adrenal with
nodular medullay hyperplasia and central necrosis showing stretched cortex overlying medullary zone (inset: numerous mitoses in
medulla). H: Control: Adrenal in 12-month-old mouse (A-D x40, E-H X 10, all sections H&E except D which was stained with AECI
hematoxylin counterstain).
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medulla (Figure 2G, inset). The cells of the cortex were
vacuolated to varying degrees. The overall size of the
adrenal gland was increased and the cortex thickness
was reduced compared with age-matched control adre-
nals (Figure 2H). Sections from testis, ovary, liver, and
kidney showed normal morphology, except for the find-
ing of a hemangioma in the liver of one transgenic animal
(data not shown).
Taken together, the morphologic data indicate that
neoplastic changes in the pituitary of the PyLT-1 trans-
genic mice are usually not apparent until after the age of
9 months and that the most pronounced morphologic
change in the adrenals of older PyLT-1 mice is a medul-
lary hyperplasia. The cells of the adrenal cortex show an
increased vacuolization, which is indicative of increased
steroid synthesis. Although the adrenal cortical observa-
tions fit a model of hypercorticotropism, the adrenal med-
ullary findings were unexpected.
Transplanted Tumors
To further characterize the biological properties of the
tumor while searching for an animal model of Cushing's
disease that exhibited shorter latency, the transgenic pi-
tuitary tumor was serially transplanted in immunocompe-
tent mice. The transplanted tumors grew slowly and in the
second passage it took about 9 months for the tumor
mass to reach approximately 1 cm in diameter. In third
and fourth passages, the tumors took only 5 months to
reach a comparable size. The male mice with trans-
planted pituitary tumors had penis and scrotal pad en-
largement similar to PyLT-1 transgenic mice and mice of
both genders showed a neck hump of increased fat de-
position. The latter sign was more apparent in female
mice.
The mice with third passage transplant tumors were
anesthetized at 6 months of age to allow for accurate
measurement of tumor size. In Figure 3 the total body
weight of the animal is plotted against the tumor diame-
ter. A positive, but weak relationship between the two
parameters was noted for males (correlation coefficient:
0.60). The tumor size ranged up to 10 mm in diameter,
and the coefficient for the regression line was 0.276. The
regression line crossed the y-axis at 38.4 g and the mean
weight of male controls was 29.6 g (SD 1.67). A stronger
correlation was found for female mice (correlation coeffi-
cient: 0.78) and the tumors were larger, up to 16 mm. The
regression coefficient was 0.7236, and the regression line
crossed the y-axis at 27.3 g, close to the mean weight of
female controls at 24.4 g (SD 1.87). Thus, female mice
that received transplants differed from their male coun-
terparts in having tumor burdens that reached a larger
Correlation between body
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Figure 3. Scatter granms with regression linesfor body weight ver-
sus tumor diameter in 6-month-old male (A) andfemale (O) mice
carrying 3rd-passage transgenic pituitary tumors (see te-xt for de-
tails).
size and they had a higher correlation between tumor
size and body weight.
Table 2 gives the weights of 6- and 9-month-old fe-
male mice that received transplants and of 9-month-old
female PyLT-1 transgenic mice, the latter from Table 1.
Comparison is made between the two age groups of
mice with transplanted pituitary tumors and between
transplanted and PyLT-1 mice of the same age. Total
body weight as well as adrenal and liver weights all show
a statistically significant increase from 6 to 9 months in
mice with transplanted tumors. A similar difference is
seen between the PyLT-1 and transplanted mice of the
same age, although the difference did not reach statisti-
cal significance for liver (P = 0.0771). For the ovaries, no
significant weight differences were found. Comparison of
the adrenal weights between Tables 1 and 2 suggest that
the transplant mice are clinically in a state of hypercorti-
cotropism at 6 months of age, and that this state is sig-
nificantly enhanced at 9 months of age (Table 2).
Pathology of Transplant Mice
In one of the six transplanted mice autopsied at 6
months of age, no palpable tumor was evident, but a 1-2
mm thick nodule of suspected tumor tissue was found by
dissection. Microscopic examination confirmed the ade-
nomatous pituitary nature of this tissue. The five other
transplanted tumors taken at the same time showed sim-
ilar histomorphology to that seen in the primary tumor but
with a higher mitotic activity (Figure 4). Immunocy-
tochemically, the transplanted tumor tissue showed the
same pattern of immunoreactivity as the primary pituitary
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Table 2. Weight Data Comparison Between Female Transplant Mice and Transgenic Mice (PyLT-1)
Parameter Group Age* Mean weight (SD) P-value
Body weight (g) Transplant 6 30.26 (3.34) 0.0201t
Transplant 9 42.33 (3.53) 0.0339t
PyLT-1 9 36.58 (6.96)
Adrenals (mg) Transplant 6 8.97 (2.09) 0.0201t
Transplant 9 19.97 (6.71) 00339t
PyLT-1 9 7.80 (0.79)
Ovaries (mg) Transplant 6 11.47 (2.26) NS
Transplant 9 13.53 (2.56) NS
PyLT-1 9 14.93 (2.91)
Liver (g) Transplant 6 1.43 (0.18) 0.0389t
Transplant 9 2.00 (0.30) NS
PyLT-1 9 1.49 (0.22)
No. of mice in each group: transplant 6-month n = 6, transplant 9-month n = 3, PyLT-1 9-month n = 4.
t Significant difference when comparing transplant mice 6- and 9-months old.
t Significant difference when comparing 9-month-old transplant mice to PyLT-1.
NS = not significant.
tumor tissue. It was immunoreactive for ACTH (Figure 4)
and negative for GH, PRL, LH, FSH, and TSH. Figure 5
illustrates the light microscopic findings for adrenals, ova-
ries, and liver in 9-month-old transplant mice compared
with control mice of the same age. The adrenal gland
from the animal with transplanted tumor is larger than the
control (Figure 5A-B) due to cortical hypertrophy. Patho-
logic abnormalities of the adrenal medulla were not re-
vealed. The ovaries showed follicular cysts in various
stages of maturation in both groups of mice, but only
ovaries in the control animals contained corpus lutea
(Figure 5C-D). The liver sections showed hydropic de-
generation in the transplanted mice and two of three liver
specimens also showed macrovesicular fatty change.
Liver sections from control mice showed no pathologic
abnormality.
Thus, the transplanted tumors shared the morpho-
logic and immunohistochemical characteristics of the pri-
mary tumors. The experimental animals showed an adre-
nal gland hypertrophy confined exclusively to the cortex.
The lack of corpora lutea would indicate ovulatory distur-
bances that are possibly due to androgen overproduc-
tion as a secondary effect of ACTH stimulation. The re-
versible injury (fatty change) seen in the liver could result
from increased gluconeogenesis by chronic ACTH stim-
ulation.
Figure 4. Photomicrograph of transplanted
pituitary tumor. Left: H&E section showing an
adenomatous tumor with numerous mitoses




The weight and histologic changes seen in both the
transgenic mice and the transplanted tumors, and the
selective ACTH immunoreactivity of the tumors strongly
indicated elevated systemic levels of ACTH in both types
of mice. Corticotropic cell adenomas can, however, oc-
cur in the absence of high blood levels of ACTH.'3 We
therefore established a radioimmunoassay for measuring
blood levels of rodent ACTH. Data for clinically ill female
PyLT-1 transgenic mice are presented in Figure 6 and
compared with control mice and mice with transplanted
tumors (2nd passage) of similar age. The median value in
the control group (n = 3) was <10 ,ugA compared with
685 ,ug/l in the transgenic (n = 4) and 1750 ,xg/l in the
transplant mice (n = 5). The median value for the trans-
genic mice was about 70-fold that of the control value
whereas the transplant group had a median value about
twofold that of the transgenic group. Both differences
were statistically significant. These data conclusively
show that the ACTH immunoreactive pituitary adenomas
in the PyLT-1 transgenic mice are functioning and asso-
ciated with elevated blood levels of ACTH. Moreover,
maximum circulating levels of ACTH were found in im-
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Figure 5. Photomicrographs of an adrenal
gland, ovary, and liver in a 9-month-old
transplant mouse (left row) and in a control
mouse (right row). The adrenal cortex is
thicker in the transplanted animal (A) than
the control (B). Sections of ovariesfrom the
transplanted mouse showfollicles at different
stages of maturation (C) but no corpus lu-
teum are seen. This is in contradiction to the
control mouse (D). A section of liver from
transplanted mouse shows fatty changes in
the hepatocytes (E) as opposed to the control
mouse (F). All sections were stained with
H&E. A-D X10, E-F X40.
Discussion
The introduction of oncogenes into the mammalian ger-
mline and their expression has resulted in the develop-
ment of tumors in a wide range of tissues in transgenic
mice.14,15 Transgenic mice carrying a hybrid gene con-
sisting of the polyoma early region promotor linked to the
polyoma large T antigen cDNA heritably develop pituitary
tumors that are positive for transgene expression (VLB,
unpublished results).8'12 We describe the pathology of
these mice and we show that they provide the first murine
model for Cushing's disease. The model adds the ad-
vantages of an in vivo system to work related to Cush-
ing's disease, and supplements in vitro studies with the
AtT-20 cell line16,17 that has been the main experimental
model in the field.
The PyLT-1 transgenic mice and especially immuno-
competent mice with transplanted PyLT-1 pituitary tu-
mors shared physical signs, histopathologic characteris-
tics and metabolic changes with Cushing's disease pa-
tients. All affected mice had elevated blood ACTH levels.
The transplant mice showed weight gains with an axial
deposition pattern that resembled the buffalo hump of
patients with Cushing's disease. The transgenic mice
and the transplant mice showed fur changes including
dull hair and loss of hair that probably correlate with the
dystrophic skin changes seen in patients. Although the
transgenic mice showed an unexpected adrenal medul-
lary hyperplasia, the transplant mice showed only a
marked hyperplasia of the adrenal cortex. Thus, the his-
topathology of the adrenal glands of the transplant mice
resembles that of Cushing's disease patients. Livers of
transplant mice showed fatty degeneration that indicated
distortions in carbohydrate metabolism. This interpreta-
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Figure 6. Median plasma ACTH in 1-year-oldfemale mice.
tion is further supported by the demonstration of hyper-
glycemia in transplant mice (AH and VLB, unpublished
data), and this condition is seen in patients with Cush-
ing's disease.
Several other transgenic mice with pituitary neoplasia
have been analyzed in addition to those reported here.
Murphy et al18 found anterior pituitary tumors in addition
to pancreatic ,B-cell tumors in mice carrying the upstream
sequences of the bovine vasopressin gene linked to
SV40 T antigen. Windle et a1'9 used the same oncogene
linked to the promotor/enhancer region of the human gly-
coprotein hormone alpha-subunit, and the resulting
transgenic mice develop anterior pituitary tumors. A
clonal cell line from these tumors synthesizes and se-
cretes alpha-subunit protein. In a third system, pituitary
hyperplasia was found in mice carrying a rat growth hor-
mone promotor-cholera toxin hybrid transgene.20 In
these models, however, there was no evidence of ACTH-
producing tumors. Thus, transgenic mouse models pres-
ently available have features that mimic various diseases
involving the anterior pituitary: multiple endocrine neopla-
sia type 1,18 gigantism,20 nonfunctional pituitary adeno-
ma,19 and Cushing's disease (present report).
Both transgenic mice and mice with transplanted tu-
mors were analyzed in this study. The primary PyLT-1
pituitary tumors were adenomas based on classic mor-
phologic features such as moderate cellular atypia and
lack of metastatic capacity. The long latency of both the
primary and the transplanted tumors is in accordance
with the growth rates of pituitary adenomas in human
patients.21 Transgenic mice showed a weight peak at 9
months of age followed by wasting. The initial weight in-
crease is most likely related to ACTH secretion from the
mircoadenoma, whereas the weight decrease seen in
older animals with a generally poor physical condition is
likely to be caused by the mass effect of the macroade-
noma. The tumor generally reached 5 mm in diameter
and compressed the midbrain and the cerebral hemi-
spheres. The mice carrying pituitary tumor transplants,
however, increased their weight far beyond the peak val-
ues of the transgenic mice and developed the axial fat
deposition pattern that mimics Cushing's disease.
The adrenal weights increased with age both in trans-
genic and in transplanted mice, but two important differ-
ences were found: the weight increase was significantly
higher in the transplanted mice, and the adrenals in these
mice showed a marked thickening of the fasciculate and
reticulate layers of the cortex, as would be expected after
ACTH overstimulation. The sick PyLT-1 mice, in contrast,
usually showed a nodular hyperplasia of the adrenal me-
dulla. The surrounding cortex seemed attenuated rather
than hypertrophic, but it should be emphasized that mor-
phometric analyses have not been performed.' The in-
creased vacuolization of the adrenal cortex in these old
transgenic mice indicates, however, that the cortical cells
were exposed to elevated ACTH levels.
There are several possible explanations for the nod-
ular hyperplasia of the adrenal medulla in the old trans-
genic mice. These include: 1) a direct stimulus on the
medulla by the glucocorticoids, 2) compression by the
pituitary macroadenoma on adjacent midbrain with al-
tered output to the adrenal medulla through the sympa-
thetic nervous system, 3) expression of the transgene in
hypothalamic cells secreting corticotropin-releasing hor-
mone (CRH), and 4) expression of the transgene in the
adrenal medulla. Although we have no direct evidence in
support of these models, we favor the hypothesis that the
transgene is expressed in the adrenal medulla for several
reasons. First, the transplant mice showed no adrenal
medullary hyperplasia, suggesting that a systemic effect
is not involved. Second, the histology of the adrenal med-
ullary hyperplasia, with numerous mitotic figures and ar-
eas of necrosis, suggests that the cells are not depen-
dent on external growth stimulation. Finally, oncogene ex-
pression in more than one neuroendocrine cell type in
transgenic mice has been previously reported.18'22 'In the
present study, we have analyzed the pituitary, the adre-
nals, the ovaries, and the testes. In forthcoming studies,
the thyroid, parathyroid, and the pancreas will be evalu-
ated for pathology.
The aged female PyLT-1 mice had to be killed at a
mean age of 13.1 (SD 2.4) months (n = 6) compared
with 15.1 (SD 0.9) months for males (n = 5). Although the
P value for the difference between the groups was sta-
tistically not significant at 6.79%, the observation sug-
gests that a sex-related growth stimulus such as estro-
gen may be involved in tumor growth. The observed
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higher maximal tumor size and higher correlation be-
tween tumor diameter and body weight in female trans-
plant mice supports this hypothesis.
Both primary pituitary tumors and the tumors trans-
planted to immunocompetent mice showed a similar his-
tomorphology, and both showed positive immunoreactiv-
ity only for ACTH and pathologically elevated levels of
ACTH in the blood. However, the transplant mice differed
in several respects from the PyLT-1 transgenic mice.
First, the latency of the transplanted tumors was shorter
and this is an advantage for experimental work. Second,
transplant mice had a marked adrenal cortical hypertro-
phy that was less complex than the adrenal pathology of
transgenic mice with hypertrophy of the adrenal medulla.
Finally, transplant mice had a consistent weight gain with
axial deposition that is characteristic of Cushing's dis-
ease rather than the wasting seen in old transgenic mice.
The mice with transplanted PyLT-1 pituitary tumors may,
therefore, be the most useful of the two murine models for
the study of Cushing's disease.
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